TW201835089A - 靶向蛋白質之化合物、組合物、方法及其用途 - Google Patents
靶向蛋白質之化合物、組合物、方法及其用途 Download PDFInfo
- Publication number
- TW201835089A TW201835089A TW106145115A TW106145115A TW201835089A TW 201835089 A TW201835089 A TW 201835089A TW 106145115 A TW106145115 A TW 106145115A TW 106145115 A TW106145115 A TW 106145115A TW 201835089 A TW201835089 A TW 201835089A
- Authority
- TW
- Taiwan
- Prior art keywords
- optionally substituted
- alkyl
- substituted
- compound
- mmol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662437400P | 2016-12-21 | 2016-12-21 | |
US62/437,400 | 2016-12-21 | ||
US201762485563P | 2017-04-14 | 2017-04-14 | |
US62/485,563 | 2017-04-14 | ||
US201762538203P | 2017-07-28 | 2017-07-28 | |
US62/538,203 | 2017-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201835089A true TW201835089A (zh) | 2018-10-01 |
Family
ID=60991575
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109142439A TWI756957B (zh) | 2016-12-21 | 2017-12-21 | 靶向蛋白質之化合物、組合物、方法及其用途 |
TW106145115A TW201835089A (zh) | 2016-12-21 | 2017-12-21 | 靶向蛋白質之化合物、組合物、方法及其用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109142439A TWI756957B (zh) | 2016-12-21 | 2017-12-21 | 靶向蛋白質之化合物、組合物、方法及其用途 |
Country Status (13)
Country | Link |
---|---|
US (4) | US10040804B2 (ru) |
EP (1) | EP3559005A1 (ru) |
JP (1) | JP2020504711A (ru) |
KR (1) | KR20190093205A (ru) |
CN (1) | CN110099907A (ru) |
AU (1) | AU2017382176A1 (ru) |
CA (1) | CA3043938A1 (ru) |
IL (1) | IL267323A (ru) |
MX (1) | MX2019007434A (ru) |
RU (1) | RU2771166C2 (ru) |
TW (2) | TWI756957B (ru) |
WO (1) | WO2018118947A1 (ru) |
ZA (1) | ZA201903479B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI756957B (zh) * | 2016-12-21 | 2022-03-01 | 美商拜歐斯瑞克斯公司 | 靶向蛋白質之化合物、組合物、方法及其用途 |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS |
EP3679028A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
AU2019243186A1 (en) * | 2018-03-30 | 2020-10-15 | Biotheryx, Inc. | Thienopyrimidinone compounds |
WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
JP7365059B2 (ja) * | 2018-06-13 | 2023-10-19 | バイオセリックス, インコーポレイテッド | 縮合チオフェン化合物 |
US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
FR3092581A1 (fr) * | 2019-02-12 | 2020-08-14 | Impact Biomedicines, Inc | Formes cristallines d'un inhibiteur de jak2 |
KR20220023343A (ko) * | 2019-05-24 | 2022-03-02 | 바이오테릭스, 인코포레이티드 | 단백질 표적 화합물, 이의 약학 조성물 및 이들의 치료적 적용 |
CA3158976A1 (en) | 2019-11-19 | 2021-05-27 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of helios protein |
CA3154073A1 (en) | 2019-12-20 | 2021-06-24 | Christopher G. Nasveschuk | Isoindolinone and indazole compounds for the degradation of egfr |
WO2021155225A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
CN115279370A (zh) | 2020-03-05 | 2022-11-01 | C4医药公司 | 用于brd9的靶向降解的化合物 |
US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
TW202227427A (zh) | 2020-09-16 | 2022-07-16 | 美商拜歐斯瑞克斯公司 | Sos1蛋白降解劑、其醫藥組合物及其治療應用 |
WO2022072538A1 (en) * | 2020-09-30 | 2022-04-07 | Biotheryx, Inc. | Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications |
US20240050428A1 (en) * | 2020-10-07 | 2024-02-15 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
TW202231269A (zh) | 2020-10-23 | 2022-08-16 | 美商拜歐斯瑞克斯公司 | Kras蛋白降解劑、其醫藥組合物及其治療應用 |
JP2024500377A (ja) | 2020-12-14 | 2024-01-09 | バイオセリックス, インコーポレイテッド | Pde4分解剤、医薬組成物、及び治療的応用 |
IL307343A (en) | 2021-04-06 | 2023-11-01 | Bristol Myers Squibb Co | Pyridinyl substituted oxisoisoindoline compounds |
WO2023283263A1 (en) | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
US20240158370A1 (en) * | 2022-09-09 | 2024-05-16 | Innovo Therapeutics, Inc. | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS |
WO2024096753A1 (en) | 2022-11-02 | 2024-05-10 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378703A (en) | 1990-04-09 | 1995-01-03 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
US5153192A (en) | 1990-04-09 | 1992-10-06 | Alcon Laboratories, Inc. | Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
US5585377A (en) | 1990-04-09 | 1996-12-17 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
DE4023048A1 (de) | 1990-07-20 | 1992-01-23 | Basf Ag | Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
AU677577B2 (en) | 1992-02-21 | 1997-05-01 | Alcon Laboratories, Inc. | Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers |
US5420923A (en) | 1993-02-16 | 1995-05-30 | Scientific-Atlanta, Inc. | Addressed messaging in a cable television system |
US5334596A (en) | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5750471A (en) | 1994-06-08 | 1998-05-12 | E. I. Du Pont De Nemours And Company | Cyclic sulfonamide herbicides |
EP0785939A1 (en) | 1994-10-11 | 1997-07-30 | Takeda Chemical Industries, Ltd. | Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors |
JP4392481B2 (ja) | 1996-02-26 | 2010-01-06 | アドヴァンスド リサーチ アンド テクノロジー インスティトゥート | 斑水腫の治療 |
ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
JPH10264532A (ja) | 1997-03-24 | 1998-10-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
US6906245B1 (en) | 1998-04-30 | 2005-06-14 | Sumitomo Chemical Company, Limited | Method for producing transgenic plants resistant to weed control compounds which disrupt the porphyrin pathways of plants |
AU753020B2 (en) | 1998-04-30 | 2002-10-03 | Sumitomo Chemical Company, Limited | Method for giving resistance to weed control compounds to plants |
JP2000159761A (ja) | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
JP4821036B2 (ja) | 1999-10-29 | 2011-11-24 | 住友化学株式会社 | 除草剤耐性植物 |
JP4821038B2 (ja) | 1999-10-29 | 2011-11-24 | 住友化学株式会社 | 除草剤耐性植物 |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
DE10133665A1 (de) | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
JP2004018434A (ja) | 2002-06-14 | 2004-01-22 | Mitsui Chemicals Inc | 新規なフッ素化イミド化合物、および該化合物を用いた電子写真感光体、電子写真装置、有機電界発光素子 |
NZ541382A (en) | 2002-12-23 | 2009-04-30 | 4Sc Ag | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
US7247736B2 (en) | 2002-12-23 | 2007-07-24 | 4Sc Ag | Method of identifying inhibitors of DHODH |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
CN100398534C (zh) | 2003-09-15 | 2008-07-02 | 天津和美生物技术有限公司 | 合成酞胺哌啶酮及其衍生物的方法 |
SE0400970D0 (sv) | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
JP2008520742A (ja) | 2004-11-23 | 2008-06-19 | ピーティーシー セラピューティクス, インコーポレイテッド | Vegf産生の阻害に有用なカルバゾール誘導体、カルボリン誘導体およびインドール誘導体 |
CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物 |
US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
ES2528316T3 (es) | 2006-09-01 | 2015-02-06 | Senhwa Biosciences, Inc. | Moduladores de la serina-treonina proteína quinasa y de PARP |
WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
CN101186612B (zh) * | 2006-11-15 | 2012-10-03 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用 |
CN101186611B (zh) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
EP1975165A1 (de) | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
JP2008273924A (ja) | 2007-03-30 | 2008-11-13 | Meiji Seika Kaisha Ltd | 2位チエニルカルバペネム誘導体 |
KR101128943B1 (ko) | 2007-04-13 | 2012-03-27 | 주식회사 엘지화학 | 디옥시피롤기를 포함하는 헤테로고리 화합물 및 이를이용한 유기 전자 소자 |
US8344160B2 (en) | 2008-10-08 | 2013-01-01 | Bristol-Myers Squibb Company | Pyrrolone melanin concentrating hormone receptor-1 antagonists |
AU2009313053A1 (en) | 2008-11-07 | 2010-05-14 | 4Sc Ag | Combinational therapy comprising DHODH inhibitor and methotrexate for treating autoimmune disease |
CA2756989A1 (en) | 2009-04-03 | 2010-10-07 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
EP2611798B1 (en) | 2010-09-01 | 2015-04-08 | Gilead Connecticut, Inc. | Pyridazinones, method of making, and method of use thereof |
US20120085992A1 (en) | 2010-09-30 | 2012-04-12 | The Regents Of The University Of California | Furan Conjugated Polymers Useful for Photovoltaic Applications |
EP2652004A2 (en) | 2010-12-15 | 2013-10-23 | Plextronics, Inc. | Fluoro monomers, oligomers, and polymers for inks and organic electronic devices |
WO2012142466A1 (en) | 2011-04-15 | 2012-10-18 | Georgia Tech Research Corporation | Stannyl derivatives of naphthalene diimides and related compositions and methods |
ITMI20110881A1 (it) | 2011-05-18 | 2012-11-19 | E T C Srl | Materiale semiconduttore organico |
WO2013052153A1 (en) | 2011-10-05 | 2013-04-11 | Georgia Tech Research Corporation | Blends of organic semiconductor compounds and electrically insulating amorphous polymers, methods and devices |
JP2014047196A (ja) | 2012-09-03 | 2014-03-17 | Sumitomo Chemical Co Ltd | 化合物及び高分子化合物、並びに、該化合物又は該高分子化合物を含有する有機半導体材料及び該有機半導体材料を用いた有機半導体素子 |
JP2014047192A (ja) | 2012-09-03 | 2014-03-17 | Sumitomo Chemical Co Ltd | 化合物、並びに、該化合物を含有する有機半導体材料、有機半導体素子 |
CN103664916B (zh) | 2012-09-12 | 2016-08-24 | 中国科学院化学研究所 | 基于联噻吩亚二吡咯及其衍生物的共轭小分子材料及其制备方法与应用 |
ITMI20121691A1 (it) | 2012-10-09 | 2014-04-10 | E T C Srl | Materiale semiconduttore organico |
ITMI20121939A1 (it) | 2012-11-15 | 2014-05-16 | E T C Srl | Materiale organico semiconduttore |
ITMI20121952A1 (it) | 2012-11-16 | 2014-05-17 | E T C Srl | Materiale semiconduttore organico |
WO2014089324A1 (en) | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
JP2014185147A (ja) | 2013-02-22 | 2014-10-02 | Mitsubishi Chemicals Corp | イミド縮合環化合物及びイミド縮合環化合物の製造方法 |
JP6248400B2 (ja) | 2013-03-15 | 2017-12-20 | 株式会社リコー | 感光体及び画像形成装置 |
JP2015013989A (ja) | 2013-06-05 | 2015-01-22 | 三菱化学株式会社 | コポリマー、半導体層形成用組成物、有機電子デバイス及び太陽電池モジュール |
WO2014204082A1 (ko) | 2013-06-20 | 2014-12-24 | 경상대학교산학협력단 | 유기 반도체 화합물, 이의 제조방법 및 이를 채용한 유기 태양전지 |
KR101595919B1 (ko) | 2013-08-30 | 2016-02-29 | 한국과학기술연구원 | 전도성 유기 반도체 화합물 및 이를 포함하는 유기태양전지 |
US9809594B2 (en) | 2013-09-10 | 2017-11-07 | University Of Washington Through Its Center For Commercialization | Non-fullerene electron acceptors for organic photovoltaic devices |
KR101732220B1 (ko) | 2014-03-31 | 2017-05-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 태양 전지 |
CN105294536B (zh) | 2014-06-30 | 2018-06-29 | 中国科学院上海有机化学研究所 | 一种制备3-亚氨基异吲哚啉酮类化合物的方法 |
AU2015305449B2 (en) * | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
CN104230953B (zh) | 2014-08-25 | 2016-08-17 | 中国科学院上海有机化学研究所 | 含2-(1,3-二硫/硒-2-亚基)乙氰共轭结构单元的萘二酰亚胺及其衍生物 |
WO2016061751A1 (en) | 2014-10-22 | 2016-04-28 | Merck Sharp & Dohme Corp. | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
CN105693745B (zh) | 2014-11-27 | 2019-07-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 有机π-共轭化合物、其制备方法及应用 |
AU2016266942B2 (en) | 2015-05-22 | 2018-10-18 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
JP2020504711A (ja) * | 2016-12-21 | 2020-02-13 | バイオセリックス, インコーポレイテッド | タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用 |
-
2017
- 2017-12-19 JP JP2019526486A patent/JP2020504711A/ja active Pending
- 2017-12-19 CA CA3043938A patent/CA3043938A1/en active Pending
- 2017-12-19 MX MX2019007434A patent/MX2019007434A/es unknown
- 2017-12-19 EP EP17829823.8A patent/EP3559005A1/en not_active Withdrawn
- 2017-12-19 AU AU2017382176A patent/AU2017382176A1/en not_active Abandoned
- 2017-12-19 KR KR1020197018882A patent/KR20190093205A/ko not_active Application Discontinuation
- 2017-12-19 US US15/847,628 patent/US10040804B2/en active Active
- 2017-12-19 WO PCT/US2017/067353 patent/WO2018118947A1/en unknown
- 2017-12-19 RU RU2019115392A patent/RU2771166C2/ru active
- 2017-12-19 CN CN201780079826.3A patent/CN110099907A/zh active Pending
- 2017-12-21 TW TW109142439A patent/TWI756957B/zh not_active IP Right Cessation
- 2017-12-21 TW TW106145115A patent/TW201835089A/zh unknown
-
2018
- 2018-06-18 US US16/011,090 patent/US10336771B2/en active Active
-
2019
- 2019-05-30 ZA ZA2019/03479A patent/ZA201903479B/en unknown
- 2019-06-13 IL IL267323A patent/IL267323A/en unknown
- 2019-06-28 US US16/457,409 patent/US10889593B2/en active Active
-
2021
- 2021-01-11 US US17/146,479 patent/US11345714B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI756957B (zh) * | 2016-12-21 | 2022-03-01 | 美商拜歐斯瑞克斯公司 | 靶向蛋白質之化合物、組合物、方法及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CA3043938A1 (en) | 2018-06-28 |
US11345714B2 (en) | 2022-05-31 |
CN110099907A (zh) | 2019-08-06 |
IL267323A (en) | 2019-08-29 |
ZA201903479B (en) | 2021-09-29 |
US10040804B2 (en) | 2018-08-07 |
AU2017382176A1 (en) | 2019-05-30 |
US20180298027A1 (en) | 2018-10-18 |
RU2019115392A3 (ru) | 2021-05-14 |
EP3559005A1 (en) | 2019-10-30 |
MX2019007434A (es) | 2019-08-16 |
TW202120514A (zh) | 2021-06-01 |
WO2018118947A1 (en) | 2018-06-28 |
US20180170948A1 (en) | 2018-06-21 |
JP2020504711A (ja) | 2020-02-13 |
US20190322683A1 (en) | 2019-10-24 |
RU2771166C2 (ru) | 2022-04-27 |
KR20190093205A (ko) | 2019-08-08 |
US10889593B2 (en) | 2021-01-12 |
US20210139500A1 (en) | 2021-05-13 |
TWI756957B (zh) | 2022-03-01 |
RU2019115392A (ru) | 2021-01-22 |
US10336771B2 (en) | 2019-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI756957B (zh) | 靶向蛋白質之化合物、組合物、方法及其用途 | |
US10562917B2 (en) | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | |
US10857155B2 (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
CN107787320B (zh) | 靶向蛋白质的化合物、其组合物、方法和用途 | |
TW202000656A (zh) | 胺基醯胺化合物 | |
CN112601751B (zh) | 稠合噻吩化合物 | |
US10584133B2 (en) | Thienopyrimidinone compounds | |
WO2019173224A1 (en) | Deuterated compounds and chimeras and uses thereof | |
BR112019018854A2 (pt) | compostos químicos |